Details of the Drug Combination

General Information of Drug Combination (ID: DCET8R2)

Drug Combination Name
Picoplatin Terameprocol
Indication
Disease Entry Status REF
Adult T acute lymphoblastic leukemia Investigative [1]
Component Drugs Picoplatin   DM0PIY6 Terameprocol   DMC3P45
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: MOLT-4
Zero Interaction Potency (ZIP) Score: 10.51
Bliss Independence Score: 8.03
Loewe Additivity Score: 3.32
LHighest Single Agent (HSA) Score: 3.33

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Picoplatin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Small-cell lung cancer 2C25.Y Phase 3 [2]
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Anaplastic large cell lymphoma DC78L8J SR Investigative [1]
Astrocytoma DCK58TP U251 Investigative [1]
Astrocytoma DC84PJ5 SNB-19 Investigative [1]
Childhood T acute lymphoblastic leukemia DCS640N CCRF-CEM Investigative [1]
Clear cell renal cell carcinoma DCAYZNM CAKI-1 Investigative [1]
Glioblastoma DCTWTFF SNB-75 Investigative [1]
Colon carcinoma DCA9WTM KM12 Investigative [4]
Adenocarcinoma DC06LX9 HT29 Investigative [5]
Adenocarcinoma DC8HATX HCT-15 Investigative [5]
High grade ovarian serous adenocarcinoma DCSNOBC NCI\\/ADR-RES Investigative [5]
Lung adenocarcinoma DCL4GX3 NCI-H522 Investigative [5]
Malignant melanoma DC7V87N UACC62 Investigative [5]
Minimally invasive lung adenocarcinoma DCSZ3FB NCI-H322M Investigative [5]
Pleural epithelioid mesothelioma DCOCPP3 NCI-H226 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976